ASSESSMENT OF THE POSSIBLE CAUSES OF DIABETES MELLITUS DEVELOPED IN PATIENTS POST COVID-19 TREATMENT IN A TERTIARY CARE HOSPITAL
Keywords:Covid-19, Type 2 diabetes mellitus, Post-covid, Uncontrolled diabetes mellitus, Newly diagnosed diabetes mellitus, Steroids, Prednisolone
Objective: Novel COVID-19 virus is extensively being studied for its long-term effects. A predominant trend of development of Diabetes Mellitus (DM) in Covid-19 patients is being observed, and hence further relation is explored in this study.
Methods: This is an observational inductive retrospective study conducted for four months in a tertiary care hospital. The study included subjects who recovered from COVID-19 and were treated post-COVID-19 in the hospital. The subjects who had stable glucose counts were excluded. The data obtained from the medical record department encompassed demographic details and clinical data of the patient. The data were tabulated, and observations were reported using descriptive analysis.
Results: Among 5632 admitted patients for COVID-19, 694 came for follow-up. 105 patients were re-admitted, but 11 had newly developed DM, and 14 observed uncontrolled DM managed by medical attention. The reported incidence rate in Newly-Diagnosed DM was 0.195%, and the person above 41 y was at greater risk. Similarly, the incidence rate in Uncontrolled-DM was 13.33%, and persons above 47 y were at greater risk. It was found that both these categories of patients had comorbidities, and the development of this was seen between the 25th-40th day. In both cases, males were more prone than females.
Conclusion: The study reports a bi-directional relationship between Covid-19 and DM. The use of steroids may have stepped-up this relationship. Cautious use of steroids, changes in the hospital formulary, and further quantitative clinical investigations are primary recommendations that may prevent such episodes.
Ren H, Yang Y, Wang F, Yan Y, Shi X, Dong K, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovascular Diabetology 2020;19:58.
Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-onset diabetes in covid-19. New England J Med 2020;383:789–90.
Suastika K, Dwipayana P, Siswadi M, Tuty RA. Age is an Important risk factor for type 2 diabetes mellitus and cardiovascular diseases. In: Glucose Tolerance. InTech; 2012.
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection; 2020. Available from: https://doi.org/10.1016/S2213. [Last accessed on 10 May 2021]
Bouhanick B, Cracowski JL, Faillie JL. Diabetes and COVID-19. Therapies 2020;75:327–33.
Pal R, Bhadada SK. COVID-19 and diabetes mellitus: an unholy interaction of two pandemics. Diabetes Metabolic Syndrome: Clin Res Rev 2020;14:513–7.
Wang W, Lu J, Gu W, Zhang Y, Liu J, Ning G. Care for diabetes with COVID-19:Advice from China. Vol. 12. Journal of Diabetes. John Wiley and Sons Inc; 2020. p. 417–9.
Peric S, Stulnig TM. Diabetes and COVID-19: Disease-management-people. Wiener Klinische Wochenschrift 2020;132:356–61.
P DJ, Kumar N DP, A VM, A R. Alterations of lipid levels may induce the insulin resistance in type two diabetes mellitus: a systemic review. Asian J Pharm Clinical Res 2020;27:9–20.
Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Vol. 17. Nature Reviews Endocrinology. Nature Research; 2021. p. 11–30.
Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao Machado LF, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 [COVID-19]. Vol. 96, Postgraduate Medical Journal. BMJ Publishing Group; 2020. p. 753–8.
Erener S. Diabetes, infection risk, and COVID-19. Vol. 39. Molecular Metabolism. Elsevier GmbH; 2020.
Qadrie ZL, Wani Sud, Gautam SP, Khan MKA. Outbreak, epidemiology, therapeutics and prevention of coronavirus disease-2019: a review. Int J Curr Pharm Res 2020;323:1824-36.
Bansal M, Walia MK. COVID 19-an overview on epidemiology, symptoms, prevention, management, treatmen, t and role of health workers. Int J Appl Pharm 2020;12:36–41.
Hartmann Boyce J, Morris E, Goyder C, Kinton J, Perring J, Nunan D, et al. Diabetes and COVID-19: Risks, management, and learnings from other national disasters. Diabetes Care 2020;43:1695–703.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/Metab Res Rev 2020;36. DOI:10.1002/dmrr.3319
World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. 46; 2006.
Demanuele F, Hines RM, Walter JR. CPP for family practice use. Six of them are from community practices and ten from teaching units. The Cumulative Patient Profile in Family Practice; 1977.
The Lancet. India’s COVID-19 emergency. Lancet [London, England] [Internet]; 2021;397:1683. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33965073. [Last accessed on 10 May 2021]
Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now? Vol. 214. Acta Tropica. Elsevier B. V.; 2021.
Nerhagen S, Moberg HL, Boge GS, Glanemann B. Prednisolone-induced diabetes mellitus in the cat: a historical cohort. J Feline Med Surgery 2021;23:175–80.
Sittig KR, Laageide LG, Akhtar Z, Wall GC, Kumar SC. Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib. IDCases; 2021. p. 24.
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Vol. 8. The Lancet Diabetes and Endocrinology. Lancet Publishing Group; 2020. p. 782–92.
Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A. Into the looking glass: Post-viral syndrome post-COVID-19. Vol. 144. Medical Hypotheses. Churchill Livingstone; 2020.
Misra P, Upadhyay RP, Misra A, Anand K. A review of the epidemiology of diabetes in rural India. Diabetes Res Clin Practice 2011;92:303–11.
Knapp S. Diabetes and infection: is there a link?-a mini-review. Gerontology 2013;59:99–104.
Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Inf 2020;26:1622–9.
Suh S, Park MK. Glucocorticoid-induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab 2017;32:180–9.
Shah M, Adel MM, Tahsin B, Guerra Y, Fogelfeld L. Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects. PLoS One 2020;15:e0231190.
Gao F, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, et al. Obesity is a risk factor for greater COVID-19 severity. Vol. 43. Diabetes Care. American Diabetes Association Inc; 2020. p. E72–4.
Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 [Covid-19]. Vol. 37. Diabetes/Metabolism Research and Reviews. John Wiley and Sons Ltd; 2021.
Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, Mendez MA, et al. Metabolism disrupting chemicals and metabolic disorders. Reproductive Toxicol 2017;68:3–33.
Rao KN, Patil N, Vidyasagar S, Manjunath Holla A. Clinical and biochemical profile of steroid-induced diabetes. Asian J Pharm Clin Res 2016;9:262-6.
Pugliese G, Vitale M, Resi V, Orsi E. Is diabetes mellitus a risk factor for Corona VIrus Disease 19 [COVID-19]? Acta Diabetol Springer Verlag Italia 2020;57:1275–85.
Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020;12:e10726.
How to Cite
Copyright (c) 2021 Khujith Rajueni, Rutuja Ambekar, Hitendrapal Solanki, Dr ABDULRAHAMAN ABUBAKAR MOMIN, Sunita Pawar
This work is licensed under a Creative Commons Attribution 4.0 International License.